INZY250117P7500
- 0.00
- 0.000.00%
Inozyme Pharma Newsroom
Piper Sandler Maintains Overweight on Inozyme Pharma, Lowers Price Target to $30
TD Cowen Maintains Inozyme Pharma(INZY.US) With Buy Rating
Inozyme Pharma (INZY) Receives a Buy From TD Cowen
Wells Fargo Maintains Inozyme Pharma(INZY.US) With Buy Rating, Maintains Target Price $11
BofA Securities Maintains Inozyme Pharma(INZY.US) With Buy Rating, Maintains Target Price $13
Analysts' Top Healthcare Picks: Inozyme Pharma (INZY), Intellia Therapeutics (NTLA)
Wells Fargo Maintains Inozyme Pharma(INZY.US) With Buy Rating, Cuts Target Price to $11
Needham Maintains Inozyme Pharma(INZY.US) With Buy Rating, Maintains Target Price $23
Inozyme Pharma Is Maintained at Buy by HC Wainwright & Co.
Inozyme Pharma Analyst Ratings
Stifel Maintains Inozyme Pharma(INZY.US) With Buy Rating, Maintains Target Price $16
H.C. Wainwright Maintains Inozyme Pharma(INZY.US) With Buy Rating, Maintains Target Price $14
Inozyme Pharma Analyst Ratings
Needham Maintains Inozyme Pharma(INZY.US) With Buy Rating, Maintains Target Price $23
TD Cowen Maintains Inozyme Pharma(INZY.US) With Buy Rating
BofA Securities Maintains Inozyme Pharma(INZY.US) With Buy Rating, Maintains Target Price $13
BofA Securities Maintains Inozyme Pharma(INZY.US) With Buy Rating, Maintains Target Price $13
Needham Maintains Inozyme Pharma(INZY.US) With Buy Rating, Maintains Target Price $23
Inozyme Pharma Price Target Maintained With a $23.00/Share by Needham
Analysts Offer Insights on Healthcare Companies: Dexcom (DXCM) and Inozyme Pharma (INZY)